The prognosis of medulloblastoma has improved significantly because of advances in multi-modal treatments; however, metastasis remains one of the prognostic factors for a poor outcome and is usually associated with tumor recurrence. We evaluated the migratory potential and therapeutic efficacy of genetically engineered human neural stem cells (NSCs) that encode a prodrug enzyme in the subdural medulloblastoma model. We genetically modified HB1.F3 (F3) immortalized human NSCs to express rabbit carboxylesterase (rCE) enzyme, which efficiently converts the prodrug CPT-11 (Irinotecan) into an active anti-cancer agent (SN-38). To simulate clinical metastatic medulloblastomas, we implanted human medulloblastoma cells into the subdural spaces of nude mice. rCE expressing NSCs (F3.rCE) were labeled with fluorescence magnetic nanoparticle for in vivo imaging. The therapeutic potential of F3.rCE was confirmed using a mouse subdural medulloblastoma model. The majority of intravenously (i.v.) injected, F3.rCE cells migrated to the subdural medulloblastoma site and a small number of F3.rCE cells were found in the lungs, pancreas, kidney and liver. Animals that received F3.rCE cells in combination with prodrug CPT-11 survived significantly longer (median survival: 142 days) than control mice that received F3.rCE cells only (median survival: 80 days, Po0.001) or CPT-11 only (median survival: 118 days, Po0.001). In conclusion, i.v. injected F3.rCE NSCs were able to target subdural medulloblastomas and demonstrate therapeutic efficacy. Our study provides data that supports further investigation of stem-cell-based gene therapy against metastatic medulloblastomas.
Introduction
Medulloblastoma is the most common malignant pediatric brain tumor and frequently disseminates via the cerebrospinal fluid. 1 Advances in multi-modal treatments using aggressive surgery, radiation, and chemotherapy have led to significant improvements in the prognosis of medulloblastomas over the past decades. However, the 5-year survival rate still ranges from 50 to 70%. 2, 3 The most common cause of death in medulloblastoma is recurrence associated with extensive cerebrospinal fluid seeding. 4, 5 Furthermore, current treatments for medulloblastomas can cause serious morbidity arising from damage to the developing brain. 4, 6 Therefore, there is a substantial need for novel and effective therapies with low toxicity for children with disseminated medulloblastomas.
Recent studies have shown that neural stem cells (NSCs) show significant migratory behavior, and selective and extensive tropism for primary brain tumors in experimental models of glioma and medulloblastoma. [7] [8] [9] In addition, NSCs can target brain metastasis in leptomeningeal medulloblastoma, breast cancer, melanoma and disseminated neuroblastoma. 8, [10] [11] [12] Therefore, we adopted NSCs as a targeting delivery system for subdural medulloblastomas, which serves as a disseminated tumor model. Gene-directed enzyme prodrug therapy has been one of the therapeutic strategies in stem cell-based gene therapy. In gene-directed enzyme prodrug therapy, an enzymeencoding gene is delivered to tumor cells, followed by administration of a prodrug, which is locally converted to a cytotoxin by the enzyme. Subsequently, enzymeproducing cells and surrounding bystanders are killed. 13 NSCs that are engineered to express a prodrug-activating enzyme are a particularly safe way to administer gene therapy, because they can kill tumor cells and nearby NSCs in the circumstance of NSCs, should they not cease dividing in vivo. 9 CPT-11 (irinotecan-7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin) is a chemotherapeutic agent that is used to treat a wide range of pediatric malignant tumors including medulloblastoma.
14 CPT-11 is activated by carboxylesterases (CE) leading to conversion to SN-38 (7-ethyl-10-hydroxycamptothecin), a topoisomerase I inhibitor. 15 The activation level of CPT-11 in human plasma is very low because of the lack of CE activity in human blood. 16 As a result, a rabbit liver CE (rCE) that is 100-fold more efficient than human CE 10, 12, [17] [18] [19] can be used for enzyme and prodrug therapy in combination with CPT-11 to improve therapeutic efficacy. 17, 19 In the present study, we administered rCE expressing NSCs intravenously (i.v.) into mice-bearing subdural medulloblastoma. The migratory potential of NSCs in live mice and their long-term therapeutic efficacy were evaluated.
Materials and methods

Cell lines
The HB1.F3 (F3) human NSCs were derived from fetal human brains at 15 weeks of gestation and were immortalized with replication-incompetent retroviral vectors containing v-myc. [20] [21] [22] HB1.F3.rCE (F3.rCE) cells were prepared by transduction with replication-deficient retrovirus that harbor the pLPCX vector, which contains the rCE gene. 12 Vectors were packaged by co-transduction of the rCE puromycin plasmid with the MV12 envelope-coding plasmid cDNA into pA317 cells. The retroviral supernatant was used for multiple infections of F3 cells. Transduced F3.rCE cells were selected with 3 mg ml À1 puromycin for 1 week. The established F3.rCE cells were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Invitrogen, Carlsbad, CA). The human medulloblastoma D283 cell line (HTB-185, ATCC, Manassas, VA) was cultured in Eagle's minimum essential medium, supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin, and 100 mg ml À1 streptomycin. All cell lines were maintained in a humidified atmosphere of 5% CO 2 at 37 1C.
RT-PCR analysis
Total RNA from F3 and F3.rCE cells was extracted with TRIzol reagent (Life Technologies, Gaithersburg, MD), as described in the supplier's instructions. The RNA, which was resuspended in 20 ml of diethyl pyrocarbonatetreated water, was quantified with the aid of a spectrophotometer (Thermospectronic, Rochester, NY) and stored at À80 1C until further use. RT-PCR was performed with the RT Premix and PCR Premix kits (Bioneer, Daejeon, Korea). For cDNA synthesis, 2 mg of total RNA and random hexamer (Promega, Madison, WI) were denatured at 70 1C for 5 min and rapidly cooled on ice, to which RT Premix was added at a final volume of 20 ml. The prepared mixture was further incubated at 42 1C for 1 h and 94 1C for 5 min. The resulting cDNAs were used for PCR using primers that are specific for the rCE gene (sense: . The PCR products were separated by electrophoresis on 1.5% agarose gels (Promega) and visualized with ethidium bromide (Bioneer). All experiments were performed three times, and the relative densities of each band were determined using a Kodak EDAS 290 gel doc system (Kodak, Rochester, NY).
CPT-11 conversion assay
The conversion of CPT-11 to SN-38 was monitored in the conditioned media of F3 and F3.rCE cells. Conditioned media was harvested after incubation of 2 Â 10 5 cells with 3 mM, 5 mM or 10 mM CPT-11 (CJ Cheiljedang, Seoul, Korea) for 72 h in 50 mM HEPES (pH 7.4, Invitrogen) at 37 1C and 5% CO 2 . The concentration of SN-38 was measured by high-performance liquid chromatographytandem mass spectrometry. In brief, solutions of CPT-11 and SN-38 (Sigma, St Louis, MO) at 0-300 ng ml À1 were mixed in acetonitrile with 20 mM ammonium acetate for use as standards. SN-38 was dissolved in dimethyl sulfoxide/methanol (50:50, v/v) at a concentration of 500 ng ml À1 for use as an internal standard. Internal standard (100 ml) was mixed with each sample and centrifuged for 3 min. Supernatant (100 ml) was mixed with 100 ml of acetonitrile containing 20 mM ammonium acetate. The mixture was centrifuged for 3 min, and the supernatant was transferred to a liquid chromatography autosampler. The concentrations of CPT-11 and SN-38 were measured using the multiple reaction monitoring function on the mass spectrometer.
In vitro evaluation of CPT-11 cytotoxicity
The cytotoxicity of CPT-11 was measured using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). All experiments were conducted in triplicate. One day before CPT-11 treatment, F3 and F3.rCE cells (4 Â 10 3 per well) were plated in 96-well culture plates. The next day, culture media was replaced with fresh media containing various concentrations of CPT-11 (0, 1, 3, 5, 10, 20 mM). After 3 days of incubation, the reaction solution was added to each well and incubated for 2 h to measure the mitochondrial dehydrogenase activities in surviving cells. The optical density ratio was determined by measuring the absorbance at 450 nm using a multi-well scanning spectrophotometer (MDS Technology, Seoul, Korea). Cell viability was expressed as the mean ± s.e. as a percentage of viable CPT-11 untreated control cells.
Subdural medulloblastoma animal model
Male, BALB/c, nude mice, aged between 4 and 6 weeks old, from Orient Bio (Sungnam, Korea), were used for in vivo studies. Mice were housed in a microisolator system in a temperature-and relative humidity-controlled environment and cared for in accordance with the Guidance for the Care and Use of Lab Animals. All procedures were performed under aseptic conditions and approved by the Experimental Animal Committee of Seoul National University.
To model leptomeningeal seeding, human medulloblastoma cells were implanted into the subdural space (n ¼ 5), modifying previously established in vivo meningioma model system. 23 Mice were anesthetized with an intraperitoneal injection of a solution of 100 mg kg À1 ketamine (Yuhan, Seoul, Korea) and 10 mg kg À1 xylazine (Bayer Korea, Ansan, Korea). Heads were fixed in the stereotactic frame (Kopf Instruments, Sunland, CA) using ear bars, and shaved. A 1-cm, midline, scalp incision was made, and the bregma was set in the same plane as the lambda by adjusting the stereotactic frame. Two small holes were made in the skull at 2.5 mm to the right of the sagittal suture and at 1 and 3 mm anterior to the lambdoid suture. A 30-gauge Hamilton syringe was inserted from the posterior hole, and 1 Â 10 5 D283 human medulloblastoma cells in 5 ml phosphate-buffered saline were injected into the subdural space. The skin was then closed.
Two months after tumor implantation, the animals were perfused with 4% paraformaldehyde under deep anesthesia and killed. Whole brains were fixed and dehydrated using elevated concentrations of sucrose. The tissues were embedded in optimum cutting temperature compound (Tissue-Tek, Torrance, CA) and stored at À80 1C. The brains were then sectioned coronally using a cryostat into 4 mm-thick slices and stained with hematoxylin and eosin. Tumor volumes were estimated using the formula for an ellipsoid and expressed as the mean ± s.e, as previously described. 24 In vivo live imaging To visualize migration of F3.rCE cells in live mice, the animals were randomized into three groups: group a, i. . 25 A deep red filter was selected to be used as the excitation filter and the emission filter. All the fluorescence images were analyzed by the spectral unmixing algorithms (available from CRI).
In vivo therapeutic efficacy and distribution of intravenously injected F3.rCE cells To examine the therapeutic efficacy of NSC-based gene therapy with F3.rCE cells and CPT-11, we undertook a study to assess the long-term survival of medulloblastoma-bearing mice. Mice harboring subdural medulloblastomas were randomly divided into four groups (n ¼ 10 in each group) as follows: group 1 received no treatment (control), group 2 received CPT-11 treatment (CPT-11 only), group 3 received F3.rCE treatment (F3.rCE cells only) and group 4 received both CPT-11 and F3.rCE cells (F3.rCE þ CPT-11). Two weeks after tumor cell implantation, 1 Â 10 6 F3.rCE cells were injected i.v. in 200 ml of phosphate-buffered saline in groups 3 and 4. Before the injections, F3.rCE cells were labeled with chloromethylbenzamido-DiI (Molecular Probes, Eugene, OR) for 30 min. One week after i.v. injection of F3.rCE cells, 7.5 mg kg À1 of CPT-11 was administered for 1 week, followed by a 1-week resting period. After the resting period, the injections of F3.rCE cells and/or CPT-11 were repeated according to the groups indicated above. Mice were maintained for 150 days or until the development of neurological symptoms requiring euthanasia.
Histology
Brains and major organs from all mice were harvested and processed as described above. Brains (4 mm-thick slices) and major organs (10 mm-thick slices) were sectioned and mounted on slides. The tissue slides were stained with 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA), and the distribution of F3.rCE cells to the subdural medulloblastoma tumor loci and the major organs (lung, pancreas, kidney and liver) was evaluated using fluorescence microscopy.
Statistics
Assessment of the cytotoxicity of CPT-11 was determined using the Mann-Whitney U-test. In vivo long-term survival data were presented as Kaplan-Meier plots and were analyzed using a log-rank (Mantel-Haenszel) method. P-values o 0.05 were considered statistically significant.
Results
Confirmation of rCE expression in transduced F3.rCE cells
The rCE transcription was found to be only expressed in F3.rCE cells, but not in the parental F3 cells (Figure 1a) . Primers targeting GAPDH were used as a positive control for the RT-PCR.
CPT-11 conversion assays
The concentration of SN-38 was increased in proportion to the CPT-11 concentration only in conditioned medium from F3.rCE cells but not from parental F3 cells, which suggests active conversion of CPT-11 to SN-38 by the rCE enzyme produced by the F3.rCE cells. SN-38 levels of 243 ± 25.35 ng ml À1 , 666 ± 116.95 ng ml À1 and 1375 ± 171.71 ng ml À1 were produced at CPT-11 concentrations of 3 mM, 5mM and 10 mM, respectively, in conditioned media from F3.rCE cells. The production of SN-38 was not detected in the conditioned media from parental F3 cells treated with CPT-11 ( Figure 1b) .
In vitro evaluation of CPT-11 cytotoxicity
The difference in the cytotoxic effects of CPT-11 in F3.rCE and F3 cells was assessed. CPT-11 cytotoxicity was not observed up to a concentration of 20 mM for F3 cells; however, the viability of F3.rCE cells dropped below 20% at a CPT-11 concentration of 1 mM (Po0.001, Figure 1c ).
Confirmation of subdural medulloblastoma
Tumor formation in the subdural space of dead or killed mice was observed (Figure 2a ). Histological analyses of the tumors revealed that the tumor masses were much larger in the subdural spaces compared with the intraparenchymal compartments (Figure 2b ). The average size of subdural tumors was 78.0 ± 7.2 mm 3 . These results show that a subdural medulloblastoma model was successfully established.
In vivo live imaging of migrating F3.rCE cells
To assess the migratory ability of F3.rCE cells in vivo, we injected fluorescence-labeled F3.rCE cells into the tail vein of mice-bearing subdural medulloblastoma. We monitored F3.rCE cells at 30 min, 1, 2, 4, 48 and 72 h after i.v. injection of labeled F3.rCE cells in live mice (Figure 3) .
At 30 min after injection of nanoparticle or labeled cells, the fluorescence signal was spread out in all groups. In group a (fluorescence control group), signal was detected in the lung at 2 h, but rapidly disappeared. In group b, labeled F3.rCE cells were trapped within the lung at 2 h and liver and kidney at 48 h and slowly disappeared. In group c, prominent fluorescence signals from F3.rCE cells were detected in the brain at 2 h. During the experimental time period, labeled F3.rCE cells accumulated in the subdural tumors with gradual clearance from other major organs compared with groups a and b. This finding indicates that i.v. injected F3.rCE cells could effectively target subdural medulloblastoma.
In vivo therapeutic effects of F3.rCE cells and CPT-11: long-term survival Therapeutic efficacy of F3.rCE cells with CPT-11 on a subdural medulloblastoma mouse model was assessed by monitoring long-term survival of all experimental groups (Figure 4a ). Using 150 days of survival as an endpoint, Kaplan-Meier plots showed a clear treatment-dependent difference in survival times among the groups (Figure 4b ). Both the CPT-11-only-treated group and the F3.rCE þ CPT-11-treated group showed prolonged survival compared with the untreated group or F3.rCE-onlytreated group (Po0.001). Mice treated with F3.rCE þ Targeting of subdural medulloblastomas using hNSC S-H Lim et al CPT-11-treated group showed significantly longer survival than mice treated with CPT-11 only (Po0.001). Notably, the F3.rCE þ CPT-11-treated group showed the longest survival (median: 142 days) with 80% of mice surviving until day 150 and none of the mice in the other three groups surviving until the endpoint.
The systemic distribution of intravenously injected NSCs
Brains and major organs were harvested, sectioned and evaluated microscopically. DiI-labeled F3.rCE cells were found mainly localized to the subdural tumor foci ( Figure 5 ). It is noted that small numbers of F3.rCE cells were found in other organs, including the lung, pancreas, kidney and liver; however, the numbers were far lower than those found in the brain. We could not detect any abnormalities, including tissue damage nor tumor formation in the major organs of F3.rCE-treated animals.
Discussion
This study provides the novel subdural medulloblastoma animal model, minimally invasive administration route of NSCs (i.v.), in vivo tracking of NSCs and long-term therapeutic efficacy of the stem cell-based prodrug gene therapy against disseminated medulloblastomas.
Most of medulloblastoma models have previously been set up by orthotopic or subcutaneous injection of tumor cells into rodents; however, these models do not accurately reflect the progression of leptomeningeal medulloblastomas. Several alternative models have been introduced to represent leptomeningeal medulloblastomas. In a previous study, we injected DAOY human medulloblastoma cells into the subarachnoid space of the cisterna magna to establish a leptomeningeal disseminated medulloblastoma. 8 However, this model was associated with high mortality, and it proved difficult to locate the exact site of seeding in vivo without additional imaging studies. We modified a Cargioli's meningioma model 23 and injected cells into the subdural space instead of the cisterna magna to simulate leptomeningeal medulloblastoma. Although this model is different from the classic leptomeningeal medulloblastoma in which tumor seeding occurs via the flow of cerebrospinal fluid, it might reflect, at least in part, tumor formation in the extraparenchymal environment and provide an easier method to locate tumor-seeding sites.
Several previous studies, including our own, have shown that NSCs have extensive potential for migration into the sites of disseminated tumor loci. 8, 11, 12 We have previously demonstrated that F3 human NSCs expressing the cytosine deaminase prodrug gene are endowed with selective migratory capacity and therapeutic effects against brain metastases from breast cancer. 11 Similarly, we reported that F3 NSCs transduced with the cytosine deaminase gene exhibit tropism and bystander killing effects for leptomeningeal medulloblastomas. 8 The results of the present study are in line with previous descriptions of NSC-based gene therapy in brain tumors and metastatic tumors.
NSC-based localized gene therapy can minimize systemic toxicities by concentrating the toxic product only locally at the tumor. 26, 27 Many enzymes, such as cytosine deaminase, deoxycytidine kinase, nitroreductase, carboxypeptidase G2 and CE, can be used. In a recent study, F3 NSCs were utilized in NSC-directed enzyme prodrug therapy for the treatment of disseminated neuroblastomas.
12 F3 NSCs adenovirally transduced to secrete rCE was adopted to target metastatic neuroblastomas and demonstrated therapeutic efficacy in the disseminated neuroblastoma animal model. In the present study, we used rCE to demonstrate 'proof of principle' for NSC-based gene therapy with CPT-11 for the treatment of leptomeningeal medulloblastomas; however, possible immunological drawbacks of rCE should be taken into consideration in the clinical setting. Therefore, future attempts should focus on the use of human CE. A recent study has indicated that a mutant human CE can induce anti-tumor activity by activating CPT-11. 28 This prodrug activating system would be a safer candidate CE enzyme system for CPT-11 conversion in clinical applications.
Implantation of NSCs can be achieved intratumorally or i.v. Intratumoral injection can reduce the distance for NSCs to migrate, which could enhance its distribution and therapeutic efficacy; however, it is not easy to carry out this type of injection because of the invasive nature of intracranial implantation. Furthermore, in the case of multiple, disseminated lesions, it is impossible to inject NSCs into every lesion site. Compared with intratumoral/ intracerebral injection, systemic injection via an i.v. route is minimally invasive and can be applied repeatedly. Our in vivo imaging study revealed accumulated fluorescence signal in the subdural tumor foci, suggesting effective i.v. delivery of NSCs to the disseminated tumors. However, less efficient targeting of the lesion and distribution on other major organs might be of concern when NSCs are injected i.v. In this study, a small number of NSCs migrated into other non-brain organs after i.v. injection. During the present study, we did not detect any tissue damage or tumor. Furthermore, although the injected stem cells are visualized by fluorescence microscopy, it is undetermined whether such DiI-labeled cells are alive or dead. As a result, more long-term follow-up observations may be needed to confirm that the stem cells in other organs are harmless. Enhancement of the tumor-tropic migratory capacity of NSCs can be achieved with cell migration modulators, such as transmembrane protein 18, 29 or multiple injections of stem cells, 7 as attempted in the this study.
In conclusion, i.v. injected human NSCs expressing rCE can target subdural medulloblastomas and prolong survival of tumor-bearing mice without any serious systemic complications. The results of the present study provide evidence of clinical potential for stem-cell-based gene therapy against disseminated medulloblastomas.
